Keywords: aspreva, completes, enrollment, pemphigus, vulgaris, trial, pharmaceuticals

Aspreva completes enrollment in pemphigus vulgaris trial

Article | 28 May 2007

Print This

Aspreva Pharmaceuticals, an emerging Canadian drug company, says it has completed enrollment in a Phase III trial of the immunosuppressent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in